“Assessing the acceptability, feasibility, effectiveness and cost-effectiveness of Long-Acting Depot Buprenorphine (LADB) for the treatment of opioid dependence in Low- and Middle-Income Countries” study
Médecins du Monde (MdM) is an independent organization of active militants providing care, bearing witness and supporting social change, both in France and internationally. For the past 40 years, we have been committed to working with the most vulnerable individuals and their communities to break down the barriers, preventing them from having access to healthcare. MdM currently works in 30 countries across all continents to facilitate access to healthcare through 6 political battles:
MdM has been present in Tanzania since 2010 and established the first comprehensive harm reduction project for PWUD in Dar es Salaam. In 2019, this project was transferred to the local NGO Mukikute, as a successor to continue providing services, while MdM remained as the technical assistance organization to continue providing technical support for local actors. MdM supported the government of Tanzania to scale up NSP (needle and syringe program) in other regions outside of Dar es Salaam. From 2022 to 2024, MdM supported Ministry of Health and local actors in Burundi to develop OAT guideline and setting up of the very first OAT program in Bujumbura.
Since 2023, MdM, together with the Burnet Institute, INPUD and the University of Bristol engaged in the CUTTS Hep C (Catalyze the Uptake of Underutilized tools for hepatitis C) project, with several research components implemented across 3 countries including Tanzania. This pilot project focuses on the prevention, screening, and treatment of hepatitis C among people who use drugs (PWUD). It aims to improve access to new or under-used prevention tools (long-acting buprenorphine and low dead space syringes), and to implement simplified screening protocols and integrated management models. It is funded by Unitaid and implemented in close collaboration with the WHO.
The study assessing long-acting depot buprenorphine (LADB) for the treatment of opioid dependence is structured as a clinical trial in Tanzania. As such, it requires the involvement of an independent trial monitor.
The Independent Clinical Trial Monitor is a member of the research unit and oversees the planning, execution, and management of the research study, ensuring it complies with regulatory requirements, GCP and ethical standards. The Independent Clinical Trial Monitor collaborates with investigators, regulatory authorities and industry partners to ensure the clinical trial is conducted efficiently and effectively. The role will support data analyses, implement best practices, and contribute to the advancement of medical knowledge and patient care.
The consultant will work closely with:
From October 2025 to December 2026
3 monitoring visits: baseline, after 6 months and before the end of the project
MdM is seeking a consultant with strong experience as research scientist and as a trial monitor for this assignment with the following qualifications, experience and competencies:
Individual consultants are invited to share the following documents by 5:00 pm East African Time, 25th July 2025 with hr.tanzania@medecinsdumonde.net with the subject line “Trial Monitor”. Late applications will not be considered. Application reviews will commence as they are received.